UNITED THERAPEUTICS CORPORATION |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 316.9 USD | +0.74% |
|
-0.66% | +44.11% |
| Jul. 08 | UBS Adjusts Price Target on United Therapeutics to $370 From $300, Maintains Buy Rating | MT |
| Jul. 01 | United Therapeutics Corporation(NasdaqGS:UTHR) added to Russell 1000 Defensive Index | CI |
Presenter SpeechUnknown Analyst (Analysts)Okay. Let's get underway. Thank you [indiscernible] ...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
United Therapeutics Corporation is a pharmaceutical company. It markets and sells commercial therapies to treat pulmonary arterial hypertension (PAH): Tyvaso DPI (treprostinil) Inhalation Powder (Tyvaso DPI); Tyvaso (treprostinil) Inhalation Solution (nebulized Tyvaso), which includes the Tyvaso Inhalation System; Remodulin (treprostinil) Injection (Remodulin); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca). Tyvaso DPI and nebulized Tyvaso are also approved to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also markets and sells an oncology product, Unituxin (dinutuximab) Injection (Unituxin) for treatment of high-risk neuroblastoma, and the Remunity Pump for Remodulin (Remunity). Tyvaso DPI is a drug-device combination product that incorporates the dry powder formulation technology and Dreamboat inhalation device technology used in MannKindâs Afrezza (insulin human) Inhalation Powder.
Calendar
2024-07-30
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
B+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
15
Last Close Price
316.9
USD
Average target price
307.5
USD
Spread / Average Target
-2.97%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +44.11% | 14.06B | |
| +17.09% | 44.63B | |
| +44.53% | 40.46B | |
| -9.70% | 38.07B | |
| +33.28% | 32.27B | |
| -8.98% | 27.3B | |
| +13.37% | 26.53B | |
| +32.33% | 12.54B | |
| -7.26% | 11.28B | |
| -14.36% | 10.43B |
- Stock Market
- Equities
- UTHR Stock
- News United Therapeutics Corporation
- Transcript : United Therapeutics Corporation Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-12-2024 04
